A Study of XB371 Administered in Participants With Locally Advanced or Metastatic Solid Tumors
ConditionSolid Tumors
Trial statusRecruiting
Trial phasePhase 1
Trial typeInterventional
Biological sexAll
Age18+
SponsorExelixis
About this trial
The primary purpose of the study is to characterize the safety and tolerability of XB371. The dose-escalation cohorts and Part B of the expansion cohorts are non-randomized. Part A of the expansion cohorts is randomized.
Eligibility criteria
Qualifiers
Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 1.
Minimum life expectancy of ≥ 12 weeks.
Recurrent locally advanced or metastatic solid tumors.
Adequate end organ and bone marrow function.
Disqualifiers
Primary brain tumors or known active brain metastases, leptomeningeal, or cranial epidural disease.
History of interstitial lung disease (ILD) of any grade or history of organizing pneumonia.
Has acute ocular infection, acute or chronic ulcerative/cicatricial condition of conjunctiva or cornea.
Known history of immunodeficiency virus (HIV) unless specific criteria are met.
Trial design
Treatments tested in this trial
- XB371
Treatment groups
150 Participants
are divided into 3 treatment groupsSponsors and collaborators
Source ClinicalTrials.gov